IL-NUCLEAI
24.6.2021 17:19:04 CEST | Business Wire | Press release
Nucleai (www.nucleaimd.com ), a precision medicine company using AI-powered image analysis technology to support novel pathology-based biomarker development, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that they have entered into a long-term collaboration to leverage Nucleai's image analysis and biomarker discovery platform for several Merck KGaA, Darmstadt, Germany clinical stage oncology assets.
As part of the collaboration, Merck KGaA, Darmstadt, Germany will leverage Nucleai’s platform for exploratory research, with the potential to further develop identified pathology-based biomarkers as companion diagnostics. The collaboration will further utilize Nucleai’s technology to expand onto Merck KGaA, Darmstadt, Germany’s analysis capabilities, enabling faster turnaround time and scale for future studies.
Nucleai's platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system's spatial characteristics, creating unique and specific histological biomarkers that may help predict patient response. These biomarkers hold the potential to provide better understanding of cancer biology, enable further stratification of responder/non-responder patient populations, and improve the success rate of clinical trials and patient care. To develop its platform, Nucleai leverages proprietary datasets of pathology images and clinical data from leading hospitals and Health Maintenance Organizations (HMOs) in the U.S and Israel.
“We are thrilled to announce another major collaboration with a leading pharmaceutical company like Merck KGaA, Darmstadt, Germany to identify and develop novel biomarkers for their oncology assets. By combining real world and clinical trial datasets, with an integrated and scalable technology platform, we are harnessing the power of AI and big data and setting the standard for future precision medicine collaborations, adds Avi Veidman, CEO and Co-Founder of Nucleai.”
About Nucleai
Nucleai is a precision medicine company that has developed an AI-powered image analysis platform to unlock the power of spatial biology from pathology images. Nucleai’s ATOM platform, built and trained off large-scale proprietary datasets, leverages computer vision and deep neural networks to structure and characterize tissue and cell architecture in pathology images to identify spatial characteristics that predict response to therapy and inform treatment decision. We are currently partnered with leading pharmaceutical companies to discover novel spatial biomarkers, develop pathology-based companion diagnostics assays and drive improved patient outcomes. For more information, please visit www.nucleaimd.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005753/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Telia to Deploy Seamless OS Following Acquisition of Telness Operator8.4.2026 13:16:00 CEST | Press release
Today, Nordic Communications Group AB, parent company of Telness Tech, announced it will divest its mobile virtual network operator (MVNO) Telness to Telia in Sweden. As part of the transaction, Telness will sign a long-term agreement with Telness Tech for continued use of the Seamless OS technology platform, ensuring a smooth digital customer experience. At closing, Telia will become the first mobile network operator (MNO) to deploy Seamless OS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408876675/en/ Telness Tech executive leadership team on the announcement that Telia will be the first Mobile Network Operator (MNO) deploying Seamless OS. From the left, Sergio Budkin; CRO, Martina Klingvall; Founder and CEO, Sebastian Stecki; CMO, Pablo Noguerol; COO, Christina Berggren; VP Customer, Delivery & Product, Jonas Cedenwing; Founder and CTO. "For Seamless OS to be brought into an MNO environment such as Telia's is a defi
NIQ and Adsquare Collaborate to Bring GeoPurchase Audiences to the Programmatic Ecosystem Across Europe and North America8.4.2026 13:00:00 CEST | Press release
Relationship enables advertisers with local audience segments based on real‑world purchase behaviors. NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced a new collaboration with Adsquare, a global location intelligence platform, to make NIQ’s GeoPurchase audience segments available within the Adsquare platform for privacy‑safe activation across Europe and North America. The relationship provides advertisers with NIQ‑built GeoPurchase segments informed by industry‑leading CPG purchase insights, enabling more precise planning and targeting across cross‑screen and digital out‑of‑home (DOOH) campaigns. NIQ’s GeoPurchase audiences are derived from anonymized, local purchase insights that reflect real‑world shopping behaviors across a wide variety of categories and retailers—not lookalike or proxy audiences. Within Adsquare’s platform, these audience segments are enriched by location‑intelligent tools that help advertisers plan and activate programmatic campaigns with
Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 20268.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Needham Virtual Healthcare Conference on April 14, 2026 and will participate in a fireside chat at 12:45 pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational
Cyviz Launches Unified Software Platform to Support Complex Environments8.4.2026 11:00:00 CEST | Press release
Cyviz AS announces the launch of its enhanced software platform, marking a milestone in the company’s strategic transition toward becoming a technology‑ and platform‑led company. The Cyviz Software Platform helps organizations monitor, manage, and optimize complex AV and IoT environments through a single, unified software layer. Across industries such as energy, defense, transportation, consulting, and large enterprise environments, organizations increasingly rely on complex, multivendor technology ecosystems to support critical operations. These are often managed using fragmented tools, resulting in limited visibility, higher operational risk, and reactive maintenance. Cyviz’ platform addresses this challenge by unifying monitoring and management across technologies, vendors, and locations. With real-time insights, proactive alerts, and centralized control, organizations can move from reactive incident handling to more predictable and resilient operations. “Many organizations are stru
Reply Selected by Microsoft as Launch Partner for Agent 365, Supporting the Governance and Scaling of AI agents8.4.2026 10:17:00 CEST | Press release
Reply [EXM, STAR: REY] has been confirmed one of a small number of Launch Partners for Agent 365, supporting the general availability of Microsoft's new platform designed to provide enterprise-grade governance, observability and lifecycle management for AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408212380/en/ Through this collaboration with Microsoft, Reply reinforces its commitment to enabling organisations to implement artificial intelligence responsibly and at scale, supporting long-term digital transformation objectives. Microsoft Agent 365 introduces a structured framework enabling organisations to deploy, monitor and manage AI agents consistently across business functions. As artificial intelligence becomes embedded in core operational processes, Agent 365 provides clarity, control and accountability, ensuring that AI-driven activities remain transparent, secure and aligned with organisational objecti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom